(CCRN) Cross Country Healthcare - Overview
Sector: Healthcare | Industry: Medical Care Facilities | Exchange: NASDAQ (USA) | Market Cap: 405m USD | Total Return: -3.3% in 12m
Avg Turnover: 8.67M
Qual. Beats: 0
Rev. Trend: -98.9%
Qual. Beats: 0
Warnings
Interest Coverage Ratio -37.0 is critical
Below Avwap Earnings
Tailwinds
Supp Ema8, Supp Ema20
Cross Country Healthcare, Inc. (CCRN) is a Florida-based talent management firm providing staffing solutions to the U.S. healthcare sector. The company operates through two primary segments: Nurse and Allied Staffing, and Physician Staffing. Its service portfolio includes temporary and permanent placement, managed services programs (MSP), and recruitment process outsourcing (RPO) for a wide range of clinical and non-clinical professionals.
The business model relies on the ongoing labor shortage within the U.S. healthcare system, where high turnover rates drive demand for flexible staffing. By acting as an intermediary between healthcare facilities and independent contractors, CCRN addresses critical gaps in acute care hospitals, schools, and government facilities. This sector is characterized by high sensitivity to nursing vacancy rates and reimbursement trends from government and private payers.
For a detailed analysis of the companys valuation metrics and historical performance, consider reviewing the data available on ValueRay.
- Travel nurse bill rates normalize as post-pandemic staffing shortages stabilize
- Managed Services Program adoption drives long-term recurring revenue and client retention
- Wage inflation for healthcare professionals pressures gross margins and profitability
- Physician staffing demand grows amid nationwide specialist and primary care shortages
- Hospital occupancy rates and elective procedure volumes dictate contingent labor utilization
| Net Income: -98.6m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.09 > 0.02 and ΔFCF/TA -10.55 > 1.0 |
| NWC/Revenue: 20.73% < 20% (prev 17.18%; Δ 3.55% < -1%) |
| CFO/TA 0.10 > 3% & CFO 47.3m > Net Income -98.6m |
| Net Debt/EBITDA: error (EBITDA <= 0) |
| Current Ratio: 3.29 > 1.5 & < 3 |
| Outstanding Shares: last quarter (31.5m) vs 12m ago -2.52% < -2% |
| Gross Margin: 19.84% > 18% (prev 0.20%; Δ 1.96k% > 0.5%) |
| Asset Turnover: 195.1% > 50% (prev 218.4%; Δ -23.29% > 0%) |
| Interest Coverage Ratio: -37.00 > 6 (EBITDA TTM -67.2m / Interest Expense TTM 2.24m) |
| A: 0.46 (Total Current Assets 298.3m - Total Current Liabilities 90.6m) / Total Assets 451.1m |
| B: 0.26 (Retained Earnings 118.9m / Total Assets 451.1m) |
| C: -0.16 (EBIT TTM -82.9m / Avg Total Assets 513.7m) |
| D: 0.85 (Book Value of Equity 117.3m / Total Liabilities 138.3m) |
| Altman-Z'' = 3.69 = AA |
| DSRI: 0.98 (Receivables 184.0m/235.0m, Revenue 1.00b/1.26b) |
| GMI: 1.02 (GM 19.84% / 20.32%) |
| AQI: 0.72 (AQ_t 0.27 / AQ_t-1 0.38) |
| SGI: 0.80 (Revenue 1.00b / 1.26b) |
| TATA: -0.32 (NI -98.6m - CFO 47.3m) / TA 451.1m) |
| Beneish M = -3.67 (Cap -4..+1) = AAA |
As of May 27, 2026, the stock is trading at USD 13.08 with a total of 313,669 shares traded.
Over the past week, the price has changed by -0.15%,
over one month by +26.99%,
over three months by +49.14% and
over the past year by -3.33%.
Cross Country Healthcare has received a consensus analysts rating of 3.00. Therefore, it is recommended to hold CCRN.
- StrongBuy: 0
- Buy: 0
- Hold: 7
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 12.4 | -4.9% |
P/E Forward = 113.6364
P/S = 0.4039
P/B = 1.2956
P/EG = 11.3652
Revenue TTM = 1.00b USD
EBIT TTM = -82.9m USD
EBITDA TTM = -67.2m USD
Long Term Debt = 1.07m USD (estimated: total debt 2.04m - short term 974k)
Short Term Debt = 974k USD (from shortTermDebt, last quarter)
Debt = 2.04m USD (from shortLongTermDebtTotal, last quarter) (leases 2.04m already included)
Net Debt = -103.5m USD (calculated: Debt 2.04m - CCE 105.6m)
Enterprise Value = 301.1m USD (404.7m + Debt 2.04m - CCE 105.6m)
Interest Coverage Ratio = -37.00 (Ebit TTM -82.9m / Interest Expense TTM 2.24m)
EV/FCF = 7.60x (Enterprise Value 301.1m / FCF TTM 39.6m)
FCF Yield = 13.15% (FCF TTM 39.6m / Enterprise Value 301.1m)
FCF Margin = 3.95% (FCF TTM 39.6m / Revenue TTM 1.00b)
Net Margin = -9.84% (Net Income TTM -98.6m / Revenue TTM 1.00b)
Gross Margin = 19.84% ((Revenue TTM 1.00b - Cost of Revenue TTM 803.1m) / Revenue TTM)
Gross Margin QoQ = 18.22% (prev 20.27%)
Tobins Q-Ratio = 0.67 (Enterprise Value 301.1m / Total Assets 451.1m)
Interest Expense / Debt = 109.6% (Interest Expense 2.24m / Debt 2.04m)
Taxrate = 21.0% (US default 21%)
NOPAT = -65.5m (EBIT -82.9m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 3.29 (Total Current Assets 298.3m / Total Current Liabilities 90.6m)
Debt / Equity = 0.01 (Debt 2.04m / totalStockholderEquity, last quarter 312.8m)
Debt / EBITDA = 1.54 (negative EBITDA) (Net Debt -103.5m / EBITDA -67.2m)
Debt / FCF = -2.61 (Net Debt -103.5m / FCF TTM 39.6m)
Total Stockholder Equity = 364.0m (last 4 quarters mean from totalStockholderEquity)
RoA = -19.20% (Net Income -98.6m / Total Assets 451.1m)
RoE = -27.10% (Net Income TTM -98.6m / Total Stockholder Equity 364.0m)
RoCE = -22.70% (EBIT -82.9m / Capital Employed (Equity 364.0m + L.T.Debt 1.07m))
RoIC = -20.85% (negative operating profit) (NOPAT -65.5m / Invested Capital 314.0m)
WACC = 7.51% (E(404.7m)/V(406.7m) * Re(7.55%) + (debt cost/tax rate unavailable))
Discount Rate = 7.55% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: -73.33 | Cagr: -4.23%
[DCF] Terminal Value 73.10% ; FCFF base≈68.3m ; Y1≈59.9m ; Y5≈48.4m
[DCF] Fair Price = 28.40 (EV 777.0m - Net Debt -103.5m = Equity 880.5m / Shares 31.0m; r=8.35% [WACC [floored]]; 5y FCF grow -15.0% → 2.50% )
EPS Correlation: N/A | EPS CAGR: N/A | SUE: 0.48 | # QB: 0
Revenue Correlation: -98.87 | Revenue CAGR: -27.83% | SUE: 0.38 | # QB: 0
EPS current Quarter (2026-06-30): EPS=0.01 | Chg30d=N/A | Revisions=-20% | Analysts=4
EPS next Quarter (2026-09-30): EPS=0.05 | Chg30d=-6.60% | Revisions=-20% | Analysts=6
EPS current Year (2026-12-31): EPS=0.09 | Chg30d=-10.54% | Revisions=-14% | GrowthEPS=+358.3% | GrowthRev=-6.8%
EPS next Year (2027-12-31): EPS=0.28 | Chg30d=+0.50% | Revisions=-14% | GrowthEPS=+207.0% | GrowthRev=+4.2%
[Analyst] Revisions Ratio: -20%